MIT researchers have invented a swallowable pill that signals when medication is taken, aiming to combat poor adherence rates among patients. The device uses a biodegradable antenna to transmit a wireless confirmation shortly after ingestion. This innovation could benefit high-risk groups like organ transplant recipients and those with chronic infections.
Medication non-adherence is a global health challenge, contributing to hundreds of thousands of preventable deaths and billions in avoidable costs each year. To address this, engineers at the Massachusetts Institute of Technology (MIT) have developed a new "smart pill" that confirms ingestion without altering the drug itself.
The system integrates into existing capsules and features a biodegradable radio frequency (RF) antenna made of zinc embedded in a cellulose particle. The pill's gelatin exterior is coated with cellulose and either molybdenum or tungsten to block signals until swallowed. Once in the stomach, the coating dissolves, allowing the antenna to receive an external signal and transmit confirmation via a small RF chip—typically within 10 minutes. The chip, measuring 400 by 400 micrometers, passes naturally through the digestive tract, while other components degrade in the stomach over about a week using safe materials like zinc and cellulose.
"We chose these materials recognizing their very favorable safety profiles and also environmental compatibility," said Giovanni Traverso, senior author of the study and an associate professor of mechanical engineering at MIT. The research, led by Mehmet Girayhan Say and Sean You, was published on January 8, 2026, in Nature Communications.
In animal tests, the device successfully sent signals from the stomach to a receiver up to 2 feet away. Future human trials could pair it with wearables to alert healthcare providers. Traverso emphasized its potential for patients needing strict regimens, such as organ transplant recipients on immunosuppressants, those treating HIV or tuberculosis, individuals with stents, and people with neuropsychiatric conditions.
"The goal is to make sure that this helps people receive the therapy they need to help maximize their health," Traverso added. Funding came from sources including Novo Nordisk and MIT's Department of Mechanical Engineering. Preclinical studies continue as the team eyes clinical applications.
